Medical disclaimer

Ropeginterferon alfa-2b vs hydroxyurea in early polycythemia vera: research by Vienna clinic doctor

In this phase 3 trial of 257 randomly assigned adults with early polycythemia vera, ropeginterferon alfa-2b did not show non-inferiority to hydroxyurea at 12 months, but responses were higher at 36 months. The patients were treated at 48 clinics in Europe, not at Confraternitaet & Goldenes Kreuz Private Clinic; one study author, Heinz Gisslinger, now practices at the clinic according to his Bookimed profile.

9 min read

Prepared by Bookimed editorial team

Medical content and care coordination

Confraternitaet & Goldenes Kreuz Private Clinic
← All research summaries
Published research, not an individual patient story.

The named clinic is an author affiliation. The study patients were not established as patients treated at that clinic.

Key takeaways

  • The trial compared ropeginterferon alfa-2b with hydroxyurea in adults with early polycythemia vera; 127 patients were treated in each group.
  • At 12 months, 26 of 122 patients on ropeginterferon alfa-2b and 34 of 123 on hydroxyurea had a complete hematological response with normal spleen size, and non-inferiority was not shown.
  • At 36 months, 50 of 95 patients on ropeginterferon alfa-2b and 28 of 74 on hydroxyurea had a complete hematological response with improved disease burden.
  • Serious treatment-related adverse events occurred in three of 127 patients on ropeginterferon alfa-2b and five of 127 on hydroxyurea.
  • These are group results from a trial and are not a forecast for any individual patient.

The question this study addresses

PROUD-PV and its extension CONTINUATION-PV were randomized, open-label phase 3 trials run in 48 clinics in Europe from 2013 to 2015 recruitment. They compared ropeginterferon alfa-2b with hydroxyurea, the standard therapy, over 3 years of treatment. The patients were treated at those European clinics and not at Confraternitaet & Goldenes Kreuz Private Clinic. Heinz Gisslinger, a hematologist at Medical University Vienna, is an author of the paper and now practices at the clinic according to the Bookimed profile. The study was funded by AOP Orphan Pharmaceuticals AG, and Bookimed did not run it.

The situation
Adults aged 18 or older with early polycythemia vera, meaning no history of cytoreductive treatment or less than 3 years of previous hydroxyurea treatment, diagnosed by the WHO 2008 criteria.
The treatment
Ropeginterferon alfa-2b by subcutaneous injection every 2 weeks, starting at 100 μg, compared with oral hydroxyurea starting at 500 mg/day.

What this evidence cannot establish

  • The patients were treated at 48 clinics in Europe, not at Confraternitaet & Goldenes Kreuz Private Clinic, so the results do not describe that clinic's own patients.
  • The trials were open-label, analyses were per-protocol, and the 36-month CONTINUATION-PV results are an interim analysis of a trial that is ongoing.
  • Most patients presented without splenomegaly, and the abstract does not give molecular response figures.

Patient groups in the published study

127 patients · Published study group

Early polycythemia vera treated with ropeginterferon alfa-2b

Indication
Early polycythemia vera
Treatment
Ropeginterferon alfa-2b subcutaneously every 2 weeks, starting at 100 μg

127 adult patients treated in the ropeginterferon alfa-2b group.

Adults with early polycythemia vera who had no cytoreductive treatment before, or less than 3 years of hydroxyurea.

Injections under the skin every 2 weeks starting at 100 μg, with an option to continue in the extension study after 1 year.

  • Composite primary endpoint: complete haematological response with normal spleen size (PROUD-PV, 12 months)

    26 / 122

    122 patients · Study group

    12 months

  • Complete haematological response without the spleen criterion (PROUD-PV, 12 months)

    53 / 123

    123 patients · Study group

    12 months

  • Complete haematological response with improved disease burden (CONTINUATION-PV, 36 months)

    50 / 95

    95 patients · Study group

    36 months

  • Complete haematological response without the spleen criterion (CONTINUATION-PV, 36 months)

    67 / 95

    95 patients · Study group

    36 months

  • Grade 3-4 treatment-related increased alanine aminotransferase

    4 / 127

    127 patients · Study group

    not stated

  • Treatment-related serious adverse events

    3 / 127

    127 patients · Study group

    not stated

Reported risks

  • Study-wide item: grade 3 and 4 treatment-related increased alanine aminotransferase occurred in four of 127 patients in this group, and treatment-related serious adverse events in three of 127.

Limits of this evidence

  • Outcomes are per-protocol, and the denominators differ between endpoints.
  • Molecular response figures are not given in the abstract.

For a clinic assessment

  • Current hematology report and blood counts with the polycythemia vera diagnosis.
  • List of previous treatments, including any hydroxyurea and its duration.

127 patients · Published study group

Early polycythemia vera treated with hydroxyurea (standard therapy)

Indication
Early polycythemia vera
Treatment
Hydroxyurea orally, starting at 500 mg/day

127 adult patients treated in the hydroxyurea comparison group.

The same early polycythemia vera population, randomly assigned 1:1 to the standard therapy.

Oral hydroxyurea starting at 500 mg/day.

  • Composite primary endpoint: complete haematological response with normal spleen size (PROUD-PV, 12 months)

    34 / 123

    123 patients · Study group

    12 months

  • Complete haematological response without the spleen criterion (PROUD-PV, 12 months)

    57 / 125

    125 patients · Study group

    12 months

  • Complete haematological response with improved disease burden (CONTINUATION-PV, 36 months)

    28 / 74

    74 patients · Study group

    36 months

  • Complete haematological response without the spleen criterion (CONTINUATION-PV, 36 months)

    38 / 74

    74 patients · Study group

    36 months

  • Grade 3-4 treatment-related leucopenia

    6 / 127

    127 patients · Study group

    not stated

  • Grade 3-4 treatment-related thrombocytopenia

    5 / 127

    127 patients · Study group

    not stated

  • Treatment-related serious adverse events

    5 / 127

    127 patients · Study group

    not stated

Reported risks

  • Study-wide item: grade 3 and 4 treatment-related leucopenia occurred in six of 127 patients and thrombocytopenia in five of 127 in this group; treatment-related serious adverse events occurred in five of 127.

Limits of this evidence

  • Three patients withdrew consent in this group.
  • Molecular response figures are not given in the abstract.

For a clinic assessment

  • Recent blood count results and spleen size measurement, if available.
  • Medication list with doses and dates for the coordinator to share with the clinic.

Results and limits of the study

At 12 months in PROUD-PV, 26 of 122 patients on ropeginterferon alfa-2b (21%) and 34 of 123 on hydroxyurea (28%) met the composite endpoint of complete hematological response with normal spleen size, and non-inferiority was not shown. Without the spleen criterion, the figures were 53 of 123 (43%) and 57 of 125 (46%). At 36 months in CONTINUATION-PV, complete hematological response with improved disease burden was met by 50 of 95 patients (53%) on ropeginterferon alfa-2b and 28 of 74 (38%) on hydroxyurea. Without the spleen criterion, 67 of 95 (71%) and 38 of 74 (51%) responded. The authors conclude that responses to ropeginterferon alfa-2b kept increasing over time.

Risks reported by the source

  • Increased gamma-glutamyltransferase at grade 3 or 4 occurred in seven of 127 patients and increased alanine aminotransferase in four of 127 on ropeginterferon alfa-2b.
  • Leucopenia at grade 3 or 4 occurred in six of 127 patients and thrombocytopenia in five of 127 on hydroxyurea.
  • One treatment-related death (acute leukaemia) was reported in the hydroxyurea group.

Limitations and unknowns

  • The abstract does not give molecular response figures.
  • Results beyond the 36-month interim analysis are not reported, because CONTINUATION-PV is ongoing.
  • Per-protocol analysis may not reflect every patient who started treatment.
  • The abstract does not say how the results apply to patients with advanced disease or longer prior treatment.

What to clarify in your treatment plan

Before booking, ask the clinic whether the doctor sees patients with early polycythemia vera and whether ropeginterferon alfa-2b is offered at the clinic. Clarify which records the doctor needs, how follow-up and blood monitoring would be arranged, and how care would continue after you return home.

Confraternitaet & Goldenes Kreuz Private Clinic: clinic profile

Confraternitaet & Goldenes Kreuz Private Clinic

Confraternitaet & Goldenes Kreuz Private Clinic

Vienna, Austria

3.8/5 · 8 Bookimed reviews (current clinic profile)

Heinz Gisslinger: doctor profile

  • Heinz Gisslinger is an author of the paper and works in the Division of Haematology and Blood Coagulation, Department of Internal Medicine I, Medical University Vienna.
  • His hematology and polycythemia vera background fits this ropeginterferon paper.
Heinz Gisslinger

Heinz Gisslinger

Hematologist/oncologist

41 years of experience

Safety and recovery: general information

General patient guidance, provided separately from the case evidence. Follow your treating team's instructions.

Possible side effects

  • Medical sources on immunotherapy list mild side effects such as fatigue, itchy rash, diarrhea, nausea and vomiting, and decreased thyroid hormone levels.

    Ask the doctor which of these can apply to your treatment and how they would be monitored.

  • Immune cells may attack healthy tissue and cause inflammation that can show up as one or more side effects.

    Report new symptoms to your care team rather than waiting.

  • Side effects may be serious and even life-threatening.

    Discuss the warning signs and the emergency plan before starting.

Recovery and aftercare

  • Most side effects are temporary, but in rare cases they can cause long-term effects and may linger after the medicine is out of your system.

    Ask how long follow-up lasts.

  • Treatment can last a long time, and side effects can occur at any point during and after treatment.

    Plan for ongoing monitoring and a local contact.

Suitability and cautions

  • You may be more likely to have a side effect if you take a combination of immunotherapy drugs or have an autoimmune disease.

    List all your medicines and conditions for the doctor.

  • If you have an autoimmune disease, it is especially important to discuss it with your health care provider before starting treatment.

    Share your full history before booking.

When to contact the clinic

  • Hepatitis can cause jaundice, dark-colored urine, stomach pain on the right side, vomiting, and increased chances of bleeding or bruising.

    Contact your doctor promptly if these appear.

  • Colitis can cause diarrhea, bloody, dark or tarry stools, and stomach pain.

    Contact your doctor promptly if these appear.

  • Lung inflammation (pneumonitis) can cause shortness of breath and a bad cough.

    Seek advice at once if breathing becomes difficult.

  • Your oncologist may advise you to call first about inflammatory symptoms, or to seek emergency medical care.

    Ask the clinic which route to follow.

Request a personal plan from the clinic

Ask Confraternitaet & Goldenes Kreuz Private Clinic about care for early polycythemia vera

Bookimed's coordinator can pass your medical records to the clinic and ask whether the doctor can review your case. The clinic then confirms what it can offer.

Ask the clinic for a current, itemized quotation. Published evidence does not establish package inclusions or a current price.

Frequently asked questions

Who ran this study and where were the patients treated?

The study was run by investigators at 48 clinics in Europe and funded by AOP Orphan Pharmaceuticals AG. The patients were treated at those clinics, not at Confraternitaet & Goldenes Kreuz Private Clinic. Author Heinz Gisslinger works at Medical University Vienna and now practices at the clinic according to his Bookimed profile. Bookimed did not run the study.

Was ropeginterferon alfa-2b better than hydroxyurea?

Not at 12 months, but results favored it at 36 months. At 12 months non-inferiority on complete hematological response with normal spleen size was not shown: 26 of 122 patients versus 34 of 123. At 36 months, 50 of 95 patients on ropeginterferon alfa-2b versus 28 of 74 on hydroxyurea had a complete response with improved disease burden. These are group results from the trial.

What side effects were reported in the study?

Serious treatment-related adverse events occurred in three of 127 patients on ropeginterferon alfa-2b and five of 127 on hydroxyurea. The most frequent grade 3 and 4 events were increased gamma-glutamyltransferase (seven patients) and increased alanine aminotransferase (four) with ropeginterferon alfa-2b, and leucopenia (six) and thrombocytopenia (five) with hydroxyurea. One treatment-related death from acute leukaemia occurred in the hydroxyurea group.

Does this study predict my own result?

No. The study reports average group results for adults with early polycythemia vera, analyzed per-protocol, and it cannot forecast an individual outcome. The 36-month data are an interim analysis of a trial that is ongoing. Your own situation, previous treatment and blood counts matter, so review them with a hematologist before deciding on any treatment.

Sources and scope

This page was prepared from the published abstract of the study and its structured results, with the clinic relation checked against the author affiliations. Safety information paraphrases medical sources on immunotherapy and is not taken from the study.

  1. 1. Gisslinger et al. – Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.

    Randomized, open-label, multicenter phase 3 trial with extension · 2020

    257 adults with early polycythemia vera randomly assigned to ropeginterferon alfa-2b or hydroxyurea in 48 European clinics

    Follow-up: Median 182·1 weeks (ropeginterferon alfa-2b) and 164·5 weeks (hydroxyurea); interim analysis at 36 months

    Only the abstract was used, so details of methods, subgroups and molecular responses are not covered.

  2. 2. Cleveland Clinic
  3. 3. National Cancer Institute
  4. 4. National Cancer Institute
  5. 5. Confraternitaet & Goldenes Kreuz Private Clinic on Bookimed
  6. 6. Heinz Gisslinger on Bookimed

Scope and limitations

  • A research summary is not an individual medical recommendation.
  • Group results describe the study participants, not a forecast for any one patient.

About the editorial team

Bookimed editorial team

Prepared by

Bookimed editorial team

Medical content and care coordination

Bookimed prepares evidence summaries from published medical sources and anonymized care records. The clinic and any doctors named on this page are identified separately in their own sections.

About this page

This page summarizes cited evidence and links to current Bookimed provider profiles. It does not replace an individual diagnosis or treatment plan. Published group results are not a guarantee of your outcome.

Clinic profiles and package availability come from the current Site catalog. Historical costs and research measurements keep their original context.

Report a correction